gms | German Medical Science

61. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC) im Rahmen der Neurowoche 2010
Joint Meeting mit der Brasilianischen Gesellschaft für Neurochirurgie am 20. September 2010

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

21. - 25.09.2010, Mannheim

Cerebral interstitial matrix metalloproteinase-9 (MMP-9) in patients following subarachnoid hemorrhage (SAH)

Meeting Abstract

  • Asita Sarrafzadeh - Division of Neurosurgery, Geneva University Hospitals, Geneva Neuroscience Center, Switzerland
  • Jean-Christophe Copin - Division of Intensive Care, Geneva University Hospitals, Geneva Neuroscience Center, Switzerland
  • Karl Schaller - Division of Neurosurgery, Geneva University Hospitals, Geneva Neuroscience Center, Switzerland
  • Philippe Bijlenga - Division of Neurosurgery, Geneva University Hospitals, Geneva Neuroscience Center, Switzerland
  • Peter Vajkoczy - Department of Neurosurgery, Charité, Universitätsmedizin Berlin
  • Yvan Gasche - Division of Intensive Care, Geneva University Hospitals, Geneva Neuroscience Center, Switzerland

Deutsche Gesellschaft für Neurochirurgie. 61. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC) im Rahmen der Neurowoche 2010. Mannheim, 21.-25.09.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. DocP1833

DOI: 10.3205/10dgnc304, URN: urn:nbn:de:0183-10dgnc3044

Veröffentlicht: 16. September 2010

© 2010 Sarrafzadeh et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: MMP-9 is involved in the pathophysiology of ischemic stroke and might play a role in delayed ischemic injury due to vasospasm in SAH patients. The aim of this pilot study, was to determine de value of brain MMP-9 in SAH patients.

Methods: Bedside microdialysis was performed in 11 SAH patients (2F/9M, 51±10 years, WFNS Grade: 2–5). Probes were placed intraoperatively in brain areas at risk for delayed cerebral ischemia. MMP-9 was measured by zymographic analysis on microdialysates obtained at the day of bleeding (D0) and daily until day seven after SAH.

Results: Mean brain MMP-9 values at day 0 were 0.02 (range: 0–0.07) pg/ml in low grade (WFNS 2; n=4) versus 4.2 (range: 0.09–17.3) pg/ml in high grade patients (WFNS 4-5; n=7). In patients developing clinically symptomatic vasospasm, mean brain MMP-9 concentration on day D0 was seven fold higher than in asymptomatic patients. In symptomatic patients MMP-9 remained elevated over the entire period of measurements, while in asymptomatic patients MMP-9 was undetectable after 24 h. In one patient with no ischemic injury, MMP-9 increased, possibly in relation to bacterial meningitis.

Conclusions: We show for the first time that brain MMP-9 is increased in poor grade SAH patients and might be considered as a potential marker of delayed cerebral ischemia. Further studies are needed to confirm our preliminary results.